Wound Skin Substitutes Market Global Analysis to 2030, Featuring Coloplast, Smith & Nephew, MTF Biologics, MiMedx, AlloSource, Organogenesis, RTI Surgical, LifeNet Health and Molecular Biologicals
Wound Biologics Market Global Analysis and Forecast to 2030, Featuring Profiles of AlloSource, LifeNet Health, Smith & Nephew, Sanara MedTech, Mtf Biologics, Becton, Dickinson, MiMedx and TissueTech
MiMedx Group, Inc.'s (NASDAQ:MDXG) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at MiMedx Group's (NASDAQ:MDXG) recent performance, when its stock has declined 11% over the past three months. But if you pay close attention, you might gath
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $MiMedx(MDXG.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.9% and a total average return of 2.1% over the p
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following
We Believe MiMedx Group's (NASDAQ:MDXG) Earnings Are A Poor Guide For Its Profitability
MiMedx Group, Inc.'s (NASDAQ:MDXG) stock rose after it released a robust earnings report. While the headline numbers were strong, we found some underlying problems once we started looking at what dro
The 20% Return This Week Takes MiMedx Group's (NASDAQ:MDXG) Shareholders Five-year Gains to 148%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more tha
Buy Rating Affirmed for MiMedx on Strong Performance and Favorable Market Outlook
MiMedx Group Up Over 18%, On Track for Largest Percent Increase Since May 2023 -- Data Talk
MiMedx Group, Inc. (MDXG) is currently at $7.28, up $1.12 or 18.18% --Would be highest close since April 1, 2024, when it closed at $7.45 --On pace for largest percent increase since May 3, 2023, wh
Express News | MiMedx Group Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Express News | HC Wainwright & Co. Reiterates Buy on MiMedx Group, Maintains $11 Price Target
MiMedx Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 67.43% HC Wainwright & Co. → $11 Reiterates Buy → Buy 03/07/2024 82.65% Lake Street → $12 Initi
MiMedx Group: Strong Financial Performance and Future Growth Potential Affirm Buy Rating
Earnings Call Summary | MiMedx(MDXG.US) Q1 2024 Earnings Conference
The following is a summary of the MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript:Financial Performance:MiMedx reported an 18% increase in Q1 revenue, reaching $85 million.The company demon
MiMedx Group Inc (MDXG) Q1 2024 Earnings Call Transcript Highlights: Strong Financial ...
MiMedx Group Q1 2024 Adj EPS $0.07 Beats $0.04 Estimate, Sales $84.709M Beat $79.361M Estimate
MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 333.33 percent increase over losses of $(0.03) per
MiMedx Group Q1 Financial and Operational Review Webcast
Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 EPS $0.07, Vs. Street Est of $0.04
04:02 PM EDT, 04/30/2024 (MT Newswires) -- Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 EPS $0.07, vs. Street Est of $0.04
Express News | MiMedx Announces First Quarter 2024 Operating and Financial Results
Express News | MiMedx Q1 Gross Profit USD 71.722 Million
No Data